SCHEMBL9371

SCHEMBL9371

CCC(=C(CC)c1ccc(OP(=O)(O)OP(=O)(O)O)cc1)c1ccc(O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.67
ESR1 P03372 11/20 0.53
ESR2 Q92731 7/20 0.53
NR1I2 O75469 3/20 0.53
KMT2A Q03164 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HIF1A Q16665 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
MEN1 O00255 1/20 0.53
USP2 O75604 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
NR3C1 P04150 1/20 0.53
TP53 P04637 1/20 0.53
FYN P06241 1/20 0.53
PGR P06401 1/20 0.53
CHRM2 P08172 1/20 0.53
ADRB1 P08588 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30306312 1.00 BLM (0.67) BLMESR1ESR2NR1I2KMT2A
SCHEMBL707840 0.88 BLM (0.87) BLMESR1ESR2NR1I2KMT2A
SCHEMBL707841 0.88 BLM (0.87) BLMESR1ESR2NR1I2KMT2A
Diethylstilbestrol SCHEMBL9373 0.86 ESR1 (0.67) BLMESR1ESR2NR1I2KMT2A
SCHEMBL329314 0.84 PTPN1 (0.44) BLMESR1ESR2KMT2ASMN1; SMN2
Diethylstilbestrol SCHEMBL21805900 0.84 ESR1 (0.55) BLMESR1ESR2NR1I2KMT2A
SCHEMBL9858001 0.82 ESR1 (0.67) ESR1ESR2NR1I2KMT2AHIF1A
SCHEMBL4254509 0.81 ESR1 (0.54) BLMESR1ESR2KMT2ASMN1; SMN2
Diethylstilbestrol Diphosphate SCHEMBL9370 0.81 BLM (1.00) BLMESR1ESR2NR1I2KMT2A
Diethylstilbestrol Diphosphate SCHEMBL6231203 0.81 BLM (1.00) BLMESR1ESR2NR1I2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2604 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735116-A2 ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2026-05-06 EP claimed
WO-2025080751-A2 ANTI-CDH17 ANTIGEN-BINDING PROTEINS AND USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2025-04-17 WO claimed
CN-119505441-A High impact resistance HPVC power tube and processing technology thereof 杭州百诺电力科技有限公司 2025-02-25 CN claimed
WO-2025006846-A2 ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2025-01-02 WO claimed
CN-115863595-A Composite cathode material and preparation method and application thereof 蜂巢能源科技(无锡)有限公司 2023-03-28 CN claimed
CN-105164152-B GLA domains as targeting agents 勇士生物科学公司 2021-07-06 CN claimed
CN-110105020-B Fair-faced concrete and preparation method thereof 佛山市政通混凝土有限公司 2021-06-01 CN claimed
CN-110828872-B High-temperature proton exchange membrane for fuel cell and preparation method thereof 江苏擎动新能源科技有限公司 2021-03-12 CN claimed
CN-112159514-A High-elasticity latex cotton for sofa and preparation method thereof 东莞戎马家具有限公司 2021-01-01 CN claimed
WO-2020081329-A1 METHODS AND COMPOSITIONS FOR MODULATING PCSK9 AND ANGPTL3 EXPRESSION CAMP4 THERAPEUTICS CORPORATION (US) 2020-04-23 WO claimed
EP-1506285-A2 COMBINATIONS OF ANTIBODIES SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND OTHER THERAPEUTIC AGENTS UAB RESEARCH FOUNDATION (US) 2005-02-16 EP claimed
WO-2004094988-A2 TOLERANCE TO GRAFT PRIOR TO THYMIC REGENERATION NORWOOD IMMUNOLOGY, LTD. (AU) 2004-11-04 WO claimed
WO-2004094649-A2 TOLERANCE TO GRAFT FOLLOWING THYMIC REACTIVATION NORWOOD IMMUNOLOGY, LTD. (AU) 2004-11-04 WO claimed
WO-2004094599-A2 DISEASE PREVENTION AND VACCINATION FOLLOWING THYMIC REACTIVATION NORWOOD IMMUNOLOGY, LTD. (AU) 2004-11-04 WO claimed
US-20030133932-A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents UAB RESEARCH FOUNDATION, THE 2003-07-17 US claimed
US-6581606-B2 Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response THE RX FILES CORPORATION 2003-06-24 US claimed
WO-2003038043-A2 COMBINATIONS OF DR5 ANTIBODY AND OTHER THERAPEUTIC AGENTS UAB RESEARCH FOUNDATION (US) 2003-05-08 WO claimed
EP-1187618-A1 PHARMACEUTICAL FORMULATIONS FOR TREATING POSTMENOPAUSAL AND PERIMENOPAUSAL WOMEN, AND THEIR USE THE GENERAL HOSPITAL CORPORATION (US) 2002-03-20 EP claimed
WO-2000074684-A1 PHARMACEUTICAL FORMULATIONS FOR TREATING POSTMENOPAUSAL AND PERIMENOPAUSAL WOMEN, AND THEIR USE THE GENERAL HOSPITAL CORPORATION (US) 2000-12-14 WO claimed
EP-0392745-B1 Immunoconjugates and prodrugs and their use in association for drug delivery CELLTECH LTD (GB) 1994-11-02 EP claimed